Live MediSum Demo

This systematic review and meta‑analysis pooled 20 studies (26 cohorts; 2,551 patients) of T‑cell‑engaging bispecific antibodies in adults with B‑cell non‑Hodgkin lymphoma or multiple myeloma and estimated a pooled total second primary malignant neoplasm (SPM) proportion of 3.5% (95% CI, 1.8%–6.9%) at a median follow‑up of 17.4 months. Study‑level pooled estimates were 3.8% for NHL and 3.4% for MM (wide CI), SPMs leading to treatment discontinuation were 2.2% (95% CI, 1.5%–3.1) and SPMs leading to death were 1.4% (95% CI, 1.1%–1.9); heterogeneous and inconsistent reporting limited assessment and authors call for standardized long‑term safety surveillance.

In a randomized, double-blind, placebo-controlled phase 3 trial in China, 322 adults with locally advanced or metastatic EGFR-variant nonsquamous NSCLC who had progressed after EGFR-TKI therapy were randomized to ivonescimab (20 mg/kg) plus pemetrexed–carboplatin versus placebo plus the same chemotherapy. Ivonescimab plus chemotherapy improved overall survival (median 16.8 vs 14.1 months; stratified HR 0.74, 95% CI 0.58–0.95; P = .02) with higher estimated 30-month survival (29.1% vs 18.4%), and grade ≥3 treatment-emergent adverse events were more frequent with ivonescimab (67.1% vs 54.7%).

This multicenter retrospective study of 114 patients who underwent surgery after neoadjuvant nivolumab plus platinum‑based chemotherapy found 21 (18.4%) required technically challenging operations (bronchoplasty, pulmonary artery angioplasty/double‑sleeve resection, or pneumonectomy), which had longer operative times and more frequent open thoracotomy. Conventional preoperative factors (T/N status, PD‑L1, radiologic response, treatment‑to‑surgery interval) did not predict complexity, whereas post‑treatment extranodal extension on preoperative assessment was the strongest predictor (univariable OR 7.06, 95% CI 1.45–34.41) and had higher positive predictive value for challenging surgery than pathological ENE, suggesting it reflects treatment‑related anatomical changes.